News InnoCan Pharma Corporation Deutsche Boerse AG

Equities

IP4

CA45783P1027

Real-time Estimate Tradegate Other stock markets 05:44:39 2024-06-03 EDT			5-day change	1st Jan Change
0.193 ^EUR	0.00%		-5.50%	-3.18%

05-27	InnoCan Pharma Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-27	Innocan Pharma Reports First Quarter 2024 Results With Revenue Growth Of Over 4X To $6.8 Million	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

InnoCan Pharma Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-27	CI
Innocan Pharma Reports First Quarter 2024 Results With Revenue Growth Of Over 4X To $6.8 Million	05-27	MT
Innocan Pharma Reports First Quarter 2024 Results with Revenue Growth of over 4X to $6.8 Million	05-27	AQ
Refile: FDA Has Granted Innocan Pharma a Meeting Date for LPT-CBD for Chronic Pain	05-21	MT
InnoCan Pharma Brief: FDA Has Granted Innocan Pharma a Meeting Date for LPT-CBD for Chronic Pain	05-21	MT
FDA Has Granted Innocan Pharma a Meeting Date for LPT-CBD for Chronic Pain	05-21	AQ
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey	05-09	AQ
Innocan Pharma Corporation Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey	05-09	CI
InnoCan Pharma Corporation Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain	04-22	CI
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain	04-22	AQ
InnoCan Pharma Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
Innocan Pharma Reports Full Year 2023 Results with Revenues up Nearly 6X to $13.7M	04-01	AQ
Innocan Pharma Corporation Announces the Signing of an Agreement with the Hebrew University	03-25	CI
InnoCan Pharma "Paves Its Way" to LPT-CBD Chemistry, Manufacturing and Controls (CMC), "Key Milestones" for FDA Approval	03-25	MT
Innocan Pharma paves its way to LPT-CBD Chemistry, Manufacturing and Controls (CMC), key milestones for FDA approval.	03-25	AQ
Innocan Pharma Announces Closing of Private Placement for Gross Proceeds of Approximately C$2 Million	03-14	AQ
InnoCan Pharma Corporation announced that it has received CAD 1.98821 million in funding	03-13	CI
Innocan Pharma Corporation Announces Tissue Distribution Study of LPT-CBD to the Brain	03-05	CI
Innocan Pharma's LPT-CBD Has the Potential to Support a new Therapeutic Venue for Neurological Disorders According to Recent Study	03-05	AQ
InnoCan Pharma Corporation announced that it expects to receive CAD 3 million in funding	03-04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News InnoCan Pharma Corporation Deutsche Boerse AG

Equities

IP4

CA45783P1027

Summary

Filters